A recent meta-analysis of randomized controlled trials demonstrated no significantly detrimental effect from SGLT2 inhibitors on the incidence of malignancies in general, or in bladder cancer in particular (Dicembrini et al., 2019). Here, SLC5A2 is linked to urinary bladder carcinoma.